Racura Oncology Presents (E,E)-Bisantrene MYC G-Quadruplex Data at FCS 2026 in Singapore

Aditi Sarkar

12 November 2026 10:15 AM AEDT

Racura Oncology Presents (E,E)-Bisantrene MYC G-Quadruplex Data at FCS 2026 in Singapore

Image Source: Krish Capital Pty Ltd

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Racura Oncology Limited (ASX:RAC) disclosed on 12 November 2026 that new preclinical data on (E,E)-bisantrene's ability to inhibit MYC gene transcription are being presented as a poster at the Frontiers in Cancer Science (FCS) 2026 Conference in Singapore, with findings identifying (E,E)-bisantrene as the active isomer that stabilises the MYC promoter G-quadruplex structure and reduces MYC gene expression and activity.

Key Points

Racura is presenting at the FCS 2026 Conference in Singapore from 11–13 November 2026, with the poster presented on 12 November 2026.
Preclinical data confirm (E,E)-bisantrene is the major isomer able to stabilise the MYC promoter G-quadruplex and inhibit MYC gene transcription and reduce MYC protein levels.
Light exposure converted (E,E)-bisantrene into less active isomers, resulting in significantly less MYC G-quadruplex stabilisation and inhibition of MYC gene expression and activity.
The findings support the use of RC220 in the EMILI, HARNESS and CPACS clinical programs.

Poster Presentation at FCS 2026 Conference

The poster, entitled "Light-Induced Isomerization Attenuates (E,E)-Bisantrene G-Quadruplex Binding and MYC Silencing," was presented at the FCS 2026 Conference held in Singapore from 11 to 13 November 2026. The study was conducted in collaboration with researchers from Racura Oncology and the University of Wollongong. The filing states that these findings build on MYC gene expression inhibition data for (E,E)-bisantrene previously presented at the 2026 American Association for Cancer Research Annual Meeting, and that Racura continues to investigate this mechanism through its ongoing research collaboration with Purdue University.

Preclinical Data on Isomer Activity and Photoisomerization

According to the filing, (E,E)-bisantrene undergoes photoisomerization in solution when exposed to light, generating mixtures of (E,E)-, (E,Z)- and (Z,Z)-bisantrene isomers. CD spectroscopy confirmed that (E,E)-bisantrene stabilises the MYC G-quadruplex, while isomer mixtures containing 62% (E,E)-bisantrene stabilised the G-quadruplex significantly less. Cell viability assays using MDA-MB-231 breast cancer cells showed an IC50 of 266 nM for 100% (E,E)-bisantrene, with decreasing (E,E)-bisantrene content in isomeric mixtures raising the IC50 to between 310 and 825 nM, indicating reduced antiproliferative activity.

Relevance to RC220 Clinical Programs

The filing states that preventing (E,E)-bisantrene photoisomerization is described as critical in clinical studies. The three active clinical programs referenced are CPACS, a Phase 1 study of RC220 with doxorubicin in advanced solid tumours (ClinicalTrials.gov ID: NCT06815575); HARNESS-1, a Phase 1 study of RC220 with osimertinib in EGFR-mutant non-small cell lung cancer (ANZCTR ID: ACTRN12626000325303); and EMILI, a Phase 2b/3 RC220 monotherapy study in relapsed/refractory acute myeloid leukaemia, for which registration is disclosed as pending. The filing attributes the following statement to Racura CEO and MD Dr Daniel Tillett: "Confirming that the (E,E)-isomer is the active form supports our development of RC220 as a proprietary formulation of (E,E)-bisantrene."

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.